The Global Cholesterol Lowering Drugs Market Size valued for USD 18.2 Billion in 2021 and is anticipated to reach USD 34.7 Billion by 2030 with a CAGR of 7.5% from 2022 to 2030.

Blood contains fat called cholesterol. Foods derived from animals, such as meat, poultry, and full-fat dairy products, contain it. It is produced by the liver. The first steps in lowering your cholesterol levels are typically changing to a healthier diet and exercising more. Nevertheless, some people might not see results from diet and lifestyle changes alone. Doctors may advise using medications to lower LDL cholesterol in these circumstances. Blood cholesterol levels may be high due to a genetic condition in some people or they may be brought on by poor dietary habits and inactivity. With a healthy diet and regular exercise, they can lower their cholesterol levels, but if they don't go as low as what is considered healthy, their doctor may prescribe medication to do so.

Cholesterol Lowering Drugs Market Dynamics

One of the main factors fueling the expansion of the market for cholesterol-lowering medications is an increase in public awareness of the dangers of bad cholesterol. Investigational studies are used by businesses to determine which medications patients tolerate well and to make adjustments in response to the findings.

Higher cholesterol rates are being reported due to rapid growth in markets like BRIC, which can be attributed to changes in diet and lifestyle due to rising wealth. As a result, there is a greater need for cholesterol-lowering treatments.

Additionally, many patents in the market for drugs that lower cholesterol are about to expire or have already done so. This indicates a rise in the use of generic substitutes, which is especially true for statins.

During the forecast period, it is anticipated that the global market for cholesterol-lowering drugs will expand moderately. New drug classes, changes in lifestyle, inactivity, and increased consumption of saturated and trans fats are some of the factors that are anticipated to spur the market growth for cholesterol-lowering medications. Additionally, rising alcohol and smoking rates raise the danger of high cholesterol, fueling market expansion. The presence of generic versions of popular brand-name medications and the severe statin side effects that cause rhabdomyolysis are anticipated to impede market expansion during the projection period. On the contrary, prosperous opportunities in developing nations are anticipated to offer promising opportunities for manufacturers in the industrial sector.

Cholesterol Lowering Drugs Market Insights

Drug class, disease type, and distribution channel are the three segments of the market for cholesterol lowering drugs. Based on the drug class, the market is segmented into seven categories: cholesterol absorption inhibitors, fibrates, fixed-dose combinations, ion exchange resins, novel cholesterol-lowering drugs, PCSK9 inhibitors, and statins. The disease type segment covers hypercholesterolemia, cardiovascular diseases, and hyperlipidemia. Furthermore, the distribution channel segment is bifurcated into retail pharmacies, hospital pharmacies, and online pharmacies.

Global Cholesterol Lowering Drugs Market Geographical Competition

Based on regional analysis, the cholesterol lowering drugs market is split into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Due to changes in lifestyle, significant investment in the healthcare sector, and an increase in heart diseases, North America is currently dominating the market. For instance, the Centers for Disease Control and Prevention estimate that 610,000 Americans pass away each year as a result of heart disease. Due to rising healthcare awareness, expanding government initiatives in the healthcare field, and an increase in research activities, Asia-Pacific is predicted to experience enormous market growth.

Global Cholesterol Lowering Drugs Industry Segment Analysis

Cholesterol Lowering Drugs Market By Drug Class

·         Cholesterol Absorption Inhibitors

·         Fibrates

·         Fixed-Dose Combinations

·         Ion Exchange Resins

·         Novel Cholesterol-Lowering Drugs

·         PCSK9 Inhibitors

·         Statins

Cholesterol Lowering Drugs Market By Disease Type

·         Cardiovascular Diseases

·         Hypercholesterolemia

·         Hyperlipidemia

Cholesterol Lowering Drugs Market By Distribution Channel

·         Retail Pharmacies

·         Hospital Pharmacies

·         Online Pharmacies

Cholesterol Lowering Drugs Market Leading Companies

The players profiled in the report are AbbVie, Inc., Amgen, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited.

Cholesterol Lowering Drugs Market Regions